Publications by authors named "Gilbert Darin Anthony Padula"
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
John D Hainsworth Kevin P Becker Tarek Mekhail Sajeel A Chowdhary Janice Faulkner Eakle Gilbert Darin Anthony Padula
J Neurooncol
September 2019
Background: Current bevacizumab-based regimens have failed to improve survival in patients with recurrent glioblastoma. To improve treatment efficacy, we evaluated bevacizumab + BKM120, an oral pan-class I PI3K inhibitor, in this patient population.
Methods: A brief phase I study established the optimal BKM120 dose to administer with standard-dose bevacizumab.